Invasive Pulmonary Aspergillosis Treatment Guidelines

Primary Treatment

The Infectious Diseases Society of America recommends voriconazole as standard of care for invasive pulmonary aspergillosis, demonstrating a significant mortality benefit with 70.8% survival at 12 weeks versus 57.9% with amphotericin B 2
Invasive pulmonary aspergillosis is a fungal infection requiring voriconazole as first-line therapy, not antibiotics, with a minimum treatment duration of 6-12 weeks 1
Without adequate antifungal therapy, invasive pulmonary aspergillosis progresses to relentless fatal pneumonia with devastating hemorrhagic infarction or progressive necrotizing pneumonia in immunocompromised patients 1

Cefepime continuation is only medically necessary if there is documented bacterial co-infection or high clinical suspicion of concurrent bacterial pneumonia, and should be discontinued after 7-8 days if cultures are negative and clinical improvement occurs on antifungals alone 4
If bacterial pneumonia is suspected, cefepime provides appropriate coverage for hospital-acquired pneumonia including Pseudomonas aeruginosa and methicillin-sensitive Staphylococcus aureus 4

Antifungal therapy for invasive pulmonary aspergillosis must continue for a minimum of 6-12 weeks, throughout the period of immunosuppression, and until lesions have resolved, as premature discontinuation leads to relapse and mortality 1, 5
Long-term therapy is facilitated by oral voriconazole in stable patients who can tolerate oral medications 1

Review recent sputum/BAL cultures and discontinue antibiotics if no bacterial pathogens were isolated and the patient has been on cefepime for >7-8 days 4
Evaluate for ongoing bacterial infection signs, such as new fever, increased purulent sputum, rising inflammatory markers, or new infiltrates on imaging, which suggest bacterial superinfection requiring continued antibiotics 4
Confirm adequate antifungal therapy by verifying the patient is receiving appropriate antifungal treatment (voriconazole or liposomal amphotericin B) with therapeutic drug monitoring if on voriconazole 2, 6